Positive Omicron data from the COVID-19 Phase II trial reported for the ABNCoV2 vaccine
Hørsholm, Denmark, May 5, 2022 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces that additional positive results for the ABNCoV2 vaccine, that is being developed as a universal booster vaccine, has been reported from the Phase II clinical trial conducted by Bavarian Nordic. The new study data demonstrates a significant boost to the neutralizing antibodies against the Omicron variant in the majority of subjects with a fold increase in the same range as previously reported for the original Wuhan SARS-CoV2 variant. Bavarian Nordic continues to